Newswire (Published: Friday, March 15, 2019, Received: Friday, March 15, 2019, 4:56:59 PM CDT)

Word Count: 443

2019 MAR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Current study results on Health and Medicine - Prostate Cancer and Prostatic Diseases have been published. According to news reporting originating in London, United Kingdom, by NewsRx journalists, research stated, “Recent technological advancements and the introduction of modern anatomical and functional sequences have led to a growing role for multiparametric magnetic resonance imaging (mpMRI) in the detection, risk assessment and monitoring of early prostate cancer. This includes men who have been diagnosed with lower-risk prostate cancer and are looking at the option of active surveillance (AS).”

Financial supporters for this research include University College London (UCL) Graduate Research Scholarship, UCLH/UCL NIHR Biomedical Research Centre, Movember, Prostate Cancer UK, National Institute for Health Research, EAU Research Foundation, Medical Research Council, Brahm PhD scholarship.

The news reporters obtained a quote from the research, “The purpose of this paper is to review the recent evidence supporting the use of mpMRI at different time points in AS, as well as to discuss some of its potential pitfalls. A combination of electronic and manual searching methods were used to identify recent, important papers investigating the role of mpMRI in AS. The high negative predictive value of mpMRI can be exploited for the selection of AS candidates. In addition, mpMRI can be efficiently used to detect higher risk disease in patients already on surveillance.”

According to the news reporters, the research concluded: “Although there is an ongoing debate regarding the precise nature of its optimal implementation, mpMRI is a promising risk stratification tool and should be considered for men on AS.”

For more information on this research see: Mri In Active Surveillance: a Critical Review. Prostate Cancer and Prostatic Diseases, 2019;22(1):5-15. Prostate Cancer and Prostatic Diseases can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - http://www.nature.com/; Prostate Cancer and Prostatic Diseases - http://www.nature.com/pcan/)

Our news correspondents report that additional information may be obtained by contacting V. Stavrinides, Ucl, Div Surg & Intervent Sci, Charles Bell House, 43-45 Foley St, London W1W 7TS, United Kingdom. Additional authors for this research include F. Giganti, M. Emberton and C.M. Moore.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/s41391-018-0077-2. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University College London
Prostate Cancer Uk
Medical Research Council

Places

Northern Europe
United Kingdom
Europe
England
London

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research